RenovoRx(RNXT.US)

Last Updated 19:00:00 ET
longbridge loading

RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript

benzinga_article·
US
RNXT
+2.90%
US
XLV
+1.10%
US
XBI
-0.69%
benzinga_article·
US
RNXT
+2.90%
US
XLV
+1.10%
US
XBI
-0.69%

RenovoRx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 563 K

Earnings Watch·
US
RNXT
+2.90%
Earnings Watch·
US
RNXT
+2.90%

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

Unusual Whales·
US
RNXT
+2.90%
US
XLV
+1.10%
US
PBE
+0.11%
Unusual Whales·
US
RNXT
+2.90%
US
XLV
+1.10%
US
PBE
+0.11%

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 | RNXT Stock News

StockTitan·
US
VHT
+0.97%
US
IHI
+1.00%
US
PBE
+0.11%
StockTitan·
US
VHT
+0.97%
US
IHI
+1.00%
US
PBE
+0.11%

RenovoRx FY25 Net Loss Widens; Expects Completing Enrolment For Phase III TIGeR-PaC In Mid 2026

nasdaq·
US
RNXT
+2.90%
nasdaq·
US
RNXT
+2.90%

RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial

Tip Ranks·
US
BBH
+0.68%
US
SBIO
-1.24%
US
LABU
-2.35%
Tip Ranks·
US
BBH
+0.68%
US
SBIO
-1.24%
US
LABU
-2.35%

RenovoRx | 10-K: FY2025 Revenue Misses Estimate at USD 1.123 M

Earnings Watch·
US
RNXT
+2.90%
Earnings Watch·
US
RNXT
+2.90%
© 2026 Longbridge｜Disclaimer